Karwatowska-Prokopczuk, Ewa
Lesogor, Anastasia
Yan, Jing-He
Hoenlinger, Angelika
Margolskee, Alison
Li, Lu
Tsimikas, Sotirios
Article History
Received: 16 July 2024
Accepted: 13 September 2024
First Online: 3 October 2024
Ethics approval and consent to participate
: The trial was performed in accordance with the guidelines of the International Council for Harmonisation and the principles of the Declaration of Helsinki. All patients provided written informed consent before enrollment.
: N/A.
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Ewa Karwatowska-Prokopczuk: Ionis Employee. Anastasia Lesogor: Novartis employee. Jing-He Yan: Novartis employee. Angelika Hoenlinger: Novartis employee. Alison Margolskee: Novartis employee. Lu Li: Ionis Employee. Sotirios Tsimikas: co-inventor and receives royalties from patents owned by University of California San Diego (UCSD) and is a co-founder and has an equity interest in Oxitope and Kleanthi Diagnostics and has a dual appointment at UCSD and Ionis Pharmaceuticals. Although these relationships have been identified for conflict-of-interest management based on the overall scope of the project, the research findings included in this publication may not necessarily relate to the interests of the above companies. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies.